Details of the Drug

General Information of Drug (ID: DMCMBHA)

• Drug Name: Erlotinib
• Synonyms: Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline

Indication

Disease Entry	ICD 11	Status	REF
Adrenal gland neoplasm	N.A.	Approved	[1]
Adult hepatocellular carcinoma	N.A.	Approved	[1]
Brain cancer	2A00	Approved	[1]
Esophageal disorder	N.A.	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Pancreatic adenocarcinoma	N.A.	Approved	[1]
Psoriasis	EA90	Approved	[1]
Salivary gland squamous cell carcinoma	N.A.	Approved	[1]
Pancreatic cancer	2C10	Phase 3	[2]
Colon cancer	2B90.Z	Phase 2	[2]
Ependymoma	2A00.0Y	Investigative	[1]
Neoplastic meningitis	N.A.	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 393.4
  Logarithm of the Partition Coefficient (xlogp); 3.3
  Rotatable Bond Count (rotbonds); 11
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Bioavailability: 59% of drug becomes completely available to its intended biological destination(s) [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.69 mL/min/kg [5]
  Elimination: 0.3% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 36.2 hours [5]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.446 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.07% [5]
  Vd: The volume of distribution (Vd) of drug is 232 L []
  Water Solubility: The ability of drug to dissolve in water is measured as 0.4 mg/mL [3]
• Chemical Identifiers:
  Formula: C22H23N3O4
  IUPAC Name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
  Canonical SMILES: COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
  InChI: InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
  InChIKey: AAKJLRGGTJKAMG-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 176870
  ChEBI ID: CHEBI:114785
  CAS Number: 183321-74-6
  DrugBank ID: DB00530
  TTD ID: D07POC
  VARIDT ID: DR00558
  INTEDE ID: DR0603
  ACDINA ID: D00239
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[11]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Drug Response	[12]

Molecular Expression Atlas of This Drug

• The Studied Disease: Adrenal gland neoplasm

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Epidermal growth factor receptor (EGFR)	DTT	EGFR	2.09E-05	0.4	190.08
Epidermal growth factor receptor (EGFR)	DTT	EGFR	6.32E-04	0.39	1.69
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.21E-01	-1.31E-01	-9.67E-02
Breast cancer resistance protein (ABCG2)	DTP	BCRP	9.24E-02	-8.49E-01	-5.22E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.80E-01	-3.78E-02	-2.75E+00
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.78E-06	-1.01E+00	-3.20E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	7.76E-01	-2.05E-01	-5.72E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.78E-01	-1.22E-03	-4.10E-03
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.73E-01	-1.42E-01	-5.35E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.09E-09	-9.49E-01	-8.32E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	5.50E-01	-9.32E-02	-1.01E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.15E-08	-6.60E-01	-3.96E+00

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Erlotinib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Erlotinib and Porfimer Sodium.	Lung cancer [2C25]	[13]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Erlotinib caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Erlotinib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[14]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[15]

Coadministration of a Drug Treating the Disease Different from Erlotinib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[16]
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[16]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Erlotinib caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[17]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Erlotinib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Erlotinib caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[14]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Erlotinib caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[14]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Erlotinib caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[14]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Erlotinib caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[14]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Erlotinib caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Erlotinib caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Rabeprazole	DMMZXIW	Major	Decreased absorption of Erlotinib due to altered gastric pH caused by Rabeprazole.	Bacterial infection [1A00-1C4Z]	[16]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Erlotinib caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Erlotinib caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[20]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[21]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Erlotinib caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Erlotinib caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
PF-04449913	DMSB068	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[17]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Erlotinib caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[14]
Anisindione	DM2C48U	Moderate	Increased plasma concentration of Erlotinib and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[19]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Erlotinib caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[14]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[23]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Erlotinib caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[24]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Erlotinib caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[14]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[16]
Primidone	DM0WX6I	Moderate	Increased metabolism of Erlotinib caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Erlotinib caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Erlotinib caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Erlotinib caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Erlotinib caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Erlotinib caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Erlotinib caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Erlotinib caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Erlotinib caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Cannabidiol.	Epileptic encephalopathy [8A62]	[17]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Erlotinib caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[14]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Erlotinib caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Erlotinib caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Erlotinib caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Dexlansoprazole	DM1DBV5	Major	Decreased absorption of Erlotinib due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[16]
Nizatidine	DMGFV3Z	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Nizatidine.	Gastro-oesophageal reflux disease [DA22]	[16]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Erlotinib caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[14]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Erlotinib caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Erlotinib caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[25]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Erlotinib caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[19]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Erlotinib caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[14]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Erlotinib caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[14]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[26]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Erlotinib caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Erlotinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Erlotinib caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Erlotinib caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Erlotinib caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Erlotinib caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Erlotinib caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Erlotinib caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Erlotinib caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[28]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[29]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[30]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[17]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Erlotinib caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Erlotinib caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[14]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[16]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Erlotinib caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[14]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Methotrexate.	Leukaemia [2A60-2B33]	[17]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[31]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Idelalisib.	Mature B-cell leukaemia [2A82]	[32]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Erlotinib caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[33]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Clofarabine.	Mature B-cell lymphoma [2A85]	[34]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[17]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Erlotinib caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[14]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Erlotinib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[14]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[35]
Exjade	DMHPRWG	Moderate	Increased metabolism of Erlotinib caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[14]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Erlotinib caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[14]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Erlotinib and Methoxsalen.	Mycosis fungoides [2B01]	[16]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Erlotinib caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Erlotinib caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Erlotinib and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[38]
Modafinil	DMYILBE	Minor	Increased metabolism of Erlotinib caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[39]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[40]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Erlotinib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[41]
Ranitidine	DM0GUSX	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Ranitidine.	Peptic ulcer [DA61]	[16]
Esomeprazole	DM7BN0X	Major	Decreased absorption of Erlotinib due to altered gastric pH caused by Esomeprazole.	Peptic ulcer [DA61]	[16]
Famotidine	DMRL3AB	Moderate	Decreased absorption of Erlotinib due to altered gastric pH caused by Famotidine.	Peptic ulcer [DA61]	[16]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Erlotinib caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[42]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Erlotinib caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[14]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Erlotinib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[14]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Erlotinib caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[14]
Riociguat	DMXBLMP	Moderate	Decreased metabolism of Erlotinib caused by Riociguat mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[29]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Erlotinib caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[14]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Erlotinib caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[14]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Erlotinib and Leflunomide.	Rheumatoid arthritis [FA20]	[29]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Erlotinib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[17]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Erlotinib caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[16]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Armodafinil	DMGB035	Minor	Increased metabolism of Erlotinib caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[39]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Erlotinib and Naltrexone.	Substance abuse [6C40]	[43]
Warfarin	DMJYCVW	Moderate	Increased plasma concentrations of Erlotinib and Warfarin due to competitive inhibition of the same metabolic pathway.	Supraventricular tachyarrhythmia [BC81]	[19]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Erlotinib due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[44]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Erlotinib caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[14]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Erlotinib caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[19]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Erlotinib 25 mg tablet	25 mg	Oral Tablet	Oral
Erlotinib 100 mg tablet	100 mg	Oral Tablet	Oral
Erlotinib 150 mg tablet	150 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Erlotinib FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [8] Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
• [9] Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
• [10] In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
• [11] Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
• [12] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [13] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [14] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
• [15] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [16] Cerner Multum, Inc. "Australian Product Information.".
• [17] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [18] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [19] Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
• [20] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [21] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [22] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [23] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [24] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [25] Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
• [26] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [27] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [28] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [29] Canadian Pharmacists Association.
• [30] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [31] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [32] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [33] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [34] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [35] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [36] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [38] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [39] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [40] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [41] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [42] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [43] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [44] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.